Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIα and altered G2/M checkpoint and apoptotic responses

Molecular Pharmacology

Volumn 57, Issue 2, 2000, Pages 296-307

  Morgan, Susan E ^a   Cadena, Rhonda S ^a   Raimondi, Susana C ^b   Beck, William T ^a,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GYRASE INHIBITOR; MERBARONE; RAZOXANE; TENIPOSIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; DNA FRAGMENTATION; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ETOPOSIDE; G2 PHASE; HUMANS; ISOENZYMES; MITOSIS; PROMOTER REGIONS (GENETICS); RAZOXANE; RNA, MESSENGER; S PHASE; SEQUENCE ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0033964621     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Adachi Y, Luke M and Laemmli UK (1991) Chromosome assembly in-vitro: Topoisomerase II is required for condensation. Cell 64:137-148.
2. Andoh T (1998) Bis (2, 6-dioxopiperazines), catalytic inhibitors of DNA topoisomerase II, as molecular probes, cardioprotectors and antitumor drugs. Biochemie 80:235-246.
3. Andoh T and Ishida R (1998) Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1400:155-171.
4. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP and Trent JM (1987) Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res 47:5455-5460.
5. Beere HM, Chresta CM and Hickman JA (1996) Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells. Mol Pharmacol 49:842-851.
6. Boege F, Andersen A, Jensen S, Zeidler R and Kreipe H (1995) Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase IIα: Delineation of a carboxylterminal epitope with peptide antibodies. Am J Pathol 146:1302-1308.
7. Bracey TS, Williams AC and Paraskeva C (1997) Inhibition of radiation-induced G2 delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal tumor cells with disrupted p53 function. Clin Cancer Res 3:1371-1381.
8. Brill SJ, Dinardo S, Voelkel-Meiman K and Sternglanz R (1987) Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA. Nature (Lond) 326:414-416.
9. Champoux JJ (1990) Mechanistic aspects of type-II topoisomerases, in DNA Topology and its Biological Effects (Cozzarelli NZ and Wang JC eds) pp 217-242, Cold Spring Harbor, New York.
10. Chen G, Wang L, Rowe T, Halligan B, Tewey K and Liu L (1984) Nonintercalative antitumor drugs interfere with the breakage reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259:13560-13566.
11. Chen M and Beck WT (1993) Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 53:5946-5953.
12. Cheng A, Balczon R, Zuo Z, Koons JS, Walsh AH and Honkanen RE (1998) Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity. Cancer Res 58:3611-3619.
13. Creighton AM, Hellmann K and Whitecross S (1969) Antitumour activity in a series of bisdiketopiperazines. Nature (Lond) 22:384-385.
14. Danks MK, Warmoth MR, Friche E, Granzen B, Bugg BY, Harker WG, Zwelling LA, Futscher BW, Suttle DP and Beck WT (1993) Single-strand conformational polymorphism analysis of the Mr 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res 53:1373-1379.
15. Downes CS, Clarke DJ, Mullinger AM, Gimenez-Ablan JF, Creighton AM and Johnson RT (1994) A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature (Lond) 372:467-470.
16. Fortune JM and Osheroff N (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J Biol Chem 273:17643-17650.
17. Gorbsky GJ (1994) Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane). Cancer Res 54:1042-1048.
18. Hasinoff BB, Kuschak TI, Creighton AM, Fattman CL, Allan WP, Thampatty P and Yalowich JC (1997) Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol 53:1843-1853.
19. Hochhauser D, Stanway CA, Harris AL and Hickson ID (1992) Cloning and characterization of the 5′ flanking region of the human topoisomerase IIα gene. J Biol Chem 267:18961-18965.
20. Holm B, Jensen PB and Sehested M (1996) ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol 38:203-209.
21. Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC and Andoh T (1995) DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res 55:2299-2303.
22. Ishida R, Sato M, Narita T, Utsumi KR, Nishimoto T, Morito T, Nagata H and Andoh T (1994) Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J Cell Biol 126:1341-1351.
23. Jensen PB, Sorensen BS, Demant EJF, Sehested M, Jensen PS, Vindelov L and Hansen HH (1990) Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 50:3311-3316.
24. Khélifa T and Beck WT (1999) Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cells. Biochem Pharmacol 58:1247-1257.
25. Kizaki H and Onishi Y (1997) Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells. Acta Enzyme Regul 37:403-423.
26. Kusumoto H, Rodgers QE, Boege F, Raimondi SC and Beck WT (1996) Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Cancer Res 56:2573-2583.
27. Mo Y-Y and Beck WT (1997) Heterogeneous expression of DNA topoisomerase IIα isoforms in tumor cell lines. Oncol Res 9:193-204.
28. Mo Y-Y, Wang Q and Beck WT (1997) Down-regulation of topoisomerase IIα in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3. Cancer Res 57:5004-5008.
29. Nelson WG, Liu LF and Coffey DS (1986) Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature (Lond) 322:87-189.
30. Robinson M and Osheroff N (1991) Effects of antineoplastic drugs on the post-strand passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry 30:1807-1813.
31. Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL and Jensen PB (1998) Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: A tyr49phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res 58:1460-1468.
32. Solary E, Bertrand R, Kohn K and Pommier Y (1993) Differential induction of apotosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood 81:1359-1368.
33. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rev M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, Blum RH, Feit F, Attubato M, Burrows W and Muggia FM (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-122.
34. Tan KB, Mattern MR, Eng WK, McCabe FL and Johnson RK (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81:1732-1735.
35. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM and Wang JC (1988) Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 85:7177-7181.
36. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K and Yanagida M (1987) DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 50:917-925.
37. Wang Q, Zambetti GP and Suttle DP (1997) Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor. Mol Cell Biol 17:389-397.
38. Wartburton PE and Earnshaw WC (1997) Untangling the role of DNA topoisomerase II in mitotic chromosome structure and function. BioEssays 19:97-99.
39. Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, Nitiss JL and Sehested M (1999) Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the walker A consensus ATP binding domain of the α isoform. Cancer Res 59:3442-3450.